GOODWILL AND OTHER INTANGIBLE ASSETS:
Changes in goodwill are as follows:
Reporting Unit
DiagnosticsCollection DevicesTotal
Balance at January 1, 2024$— $35,696 $35,696 
Acquisition6,388 — 6,388 
Change related to foreign currency translation— (1,754)(1,754)
Balance at December 31, 20246,388 33,942 40,330 
Acquisition1,775 — 1,775 
Change related to foreign currency translation— 1,258 1,258 
Balance at December 31, 2025$8,163 $35,200 $43,363 
On November 30, 2025, the Company performed its quantitative annual goodwill impairment test. The Company utilizes a combination of the income approach and market approach in determining the fair value of its two reporting units. The test concluded that the carrying value of the Company's reporting units was below fair value indicating there was no impairment of goodwill.
Intangible assets consist of the following:
 December 31, 2025
Amortization
Period (Years)
GrossAccumulated Amortization Net
Definite Life Intangible Assets
Customer relationships10$9,134 $(9,134)$— 
Patents and product rights57,596 (7,596)— 
Developed technology
7-15
8,995 (7,095)1,900 
Trade names
5-15
3,501 (3,355)146 
29,226 (27,180)2,046 
Indefinite Life Intangible Assets
IPR&D technology (Note 13)N/A17,000 — 17,000 
$46,226 (27,180)19,046 
December 31, 2024
Amortization
Period (Years)
GrossAccumulated
Amortization
Net
Definite Life Intangible Assets
Customer relationships10$10,858 $(10,858)$— 
Patents and product rights57,495 (7,399)96 
Developed technology
7-10
10,169 (10,169)— 
Trade names
5-15
4,327 (3,988)339 
32,848 (32,413)435 
Indefinite Life Intangible Assets
IPR&D technology (Note 13)N/A17,000 — 17,000 
$49,848 $(32,413)$17,435 
During 2023, the Company identified a triggering event to test for the recoverability of intangible assets given the decline in the Company's market capitalization leading up to and as of its annual goodwill impairment testing date. The Company performed an undiscounted cash flow analysis and determined the carrying value of the developed technology, trade names, and customer relationships intangible assets could not be recovered through the sum of the undiscounted future
cash flows. The Company used an income approach to determine the fair value of the developed technology and customer relationships intangible assets and the relief from royalty method for the trade names. As a result of this analysis, the Company determined the intangible assets associated with Diversigen and Novosanis were impaired as the fair value of the developed technology, trade names, and customer relationships did not exceed their carrying value. The Company recognized a pre-tax impairment charge of $6.2 million during the year ended December 31, 2023, which is reported in loss on impairments in the Company's consolidated statement of operations.
Also in 2023, the Company determined that its remaining developed technology intangible asset was fully impaired. As a result of failed stability studies, the Company decided to no longer pursue the technology. The Company recognized a pre-tax impairment charge of $2.4 million during the year ended December 31, 2023 which is reported in loss on impairments in the Company's consolidated statement of operations.
Amortization expense for 2025, 2024, and 2023 was $0.3 million, $0.7 million, and $2.0 million, respectively.
Amortization expense for each of the five succeeding fiscal years and beyond is estimated as follows:
2026$336 
2027190 
2028190 
2029190 
2030190 
Beyond950 
$2,046 

Historical Timeline

Fiscal YearFiled
2025Mar 9, 2026Showing above
2024Mar 7, 2025
2023Mar 11, 2024
2022Mar 3, 2023

About Goodwill & Intangibles Disclosures

Goodwill and intangible asset disclosures reveal the premium paid in acquisitions and how management assesses whether that premium retains its value. Since goodwill is no longer amortized under US GAAP, the annual impairment test is the only mechanism that adjusts carrying values downward — making the assumptions behind that test critically important for investors.

Key signals: a history of goodwill impairments suggests management consistently overpays for acquisitions. Watch the gap between reporting unit fair value and carrying amount — when fair value exceeds carrying amount by less than 10-20%, a small decline in business performance could trigger a write-down. For finite-lived intangibles, examine useful life assumptions across customer relationships, technology, and trade names; aggressive estimates inflate near-term earnings. Compare total intangibles-to-total-assets ratios against peers to assess acquisition dependency. Rising goodwill as a percentage of equity can signal balance sheet fragility.